KDR and neoplasm: Our study supports the feasibility of TTAC-0001 providing therapeutic benefits in glioblastoma and colorectal cancer through inhibitory effects of tumor-associated angiogenesis by preventing VEGF from binding to VEGFR-2/KDR.